Introduction c-myc is a proto-oncogene of the basic-helix-loop-helix leucine zipper (bHLHZ) family of transcription factors. Myc protein forms dimers with another bHLHZ, Max, and binds the E-Box DNA sequence to activate transcription of several genes (Luscher and Larsson, 1999) . The Myc-mediated transcriptional activity is antagonized by Mad bHLHZ proteins, which competitively bind Max and the same E-box sequences, repressing transcription. Myc also possesses a repressive potential, as it directly reduces the expression of several genes (Gartel and Shchors, 2003) . Myc regulates diverse cellular processes integral to cell growth, survival, and development, and its misregulation leads to cancer (Nesbit et al., 1999) . The Promyelocytic Leukaemia (PML) gene was originally identified in patients affected by Acute Promyelocytic Leukaemia (APL), where it is fused to the retinoic acid receptor a (RARa) gene upon a t(15;17) chromosomal translocation (de The et al., 1991; Goddard et al., 1991) . This translocation event accounts for 99% of APL cases. PML is a phosphoprotein belonging to the TRIM/RBCC family (Reymond et al., 2001) , which localizes within discrete nuclear structures called nuclear bodies (NB), PML oncogenic domains (PODs), or nuclear domain 10 (ND10) (Hodges et al., 1998) . PML localization to the NB is a prerequisite for the formation and the maintenance of their macromolecular structure (Ishov et al., 1999; Zhong et al., 2000) . The NB associate with the nuclear matrix , and interact with several proteins that are responsible for DNA stability and repair (Zhong et al., 1999; Naka et al., 2002) . Increased PML protein levels inhibit proliferation (Koken et al., 1995; Liu et al., 1995) , and this effect mainly occurs through gene expression control, as the NB are also involved in the activation and repression of many genes by sequestering and modulating the post-translational status of several transcription factors .
There is growing evidence that PML acts as a tumour suppressor gene . Conversely, Myc expression is associated to uncontrolled cell proliferation and genomic instability, mainly by positive regulation of genes that promote cell growth and proliferation and by negative regulation of genes that induce cytostatic effects and DNA surveillance (Seoane et al., 2002; Chiang et al., 2003; Grandori et al., 2003) . Noteworthy, 15-40% of patients with APL and t(15;17) have complete or partial trisomy of chromosome 8 as secondary defect, and the smallest region of gain corresponds to 8q23-24, where c-myc gene maps (Zimonjic et al., 2000; Le Beau et al., 2002 , 2003 . As well, PML/RARa transgenic mice develop chromosomal alteration in leukemic cells, the majority of which are represented by trisomy of chromosome 15 band D2-3, where murine c-myc maps. The observation that Myc tumorigenic pathway is preferentially selected in these malignancies suggests that PML may be necessary to survey Myc activity. PML is required for the transcriptional repression of Mad target genes, the majority of which are shared with Myc (Khan et al., 2001; Luscher, 2001; Nikiforov et al., 2003) . On the basis of these suggestions, we investigated a possible involvement of PML in Myc activity.
Results

PML influences the expression profile of several Myc target genes
In order to determine whether PML plays a role in Myc transcriptional activity, we performed a widespread comparative analysis of mRNA expression levels and promoter occupancy of Myc direct target genes in wt and PMLÀ/À MEFs (Wang et al., 1998) . c-myc is an early serum response gene, its expression peaks in the early G1 phase and rapidly decreases as cells enter the S phase (Henriksson and Luscher, 1996) . In order to follow the events that occur during this time frame, wt (Table 1) . (c) The graphics indicate the percentage of genes that show increased expression in MEFs wt (grey), PMLÀ/À (black), or that show no difference (white) in the G0 (t0), in the early and middle G1 (t6 and t12), and in the late G1/early S phase (t16) and PMLÀ/À MEFs were synchronized by serum starvation, and harvested in G0 (t0 time point) and 6, 12, 16, and 20 h after serum addition. The expression profile of c-myc and the S phase marker Ccnb1 using real-time quantitative PCR confirmed the efficacy of synchronization (Figure 1a) . Consistently, Myc protein was equally represented in the two cell types. The stability of endogenous or adenovirus-infected Myc in the two cell types was assessed using cycloheximide to block protein synthesis, and no significant difference in Myc turnover was observed (data not shown). We also monitored the proper expression of PML mRNA in wt MEFs, which has been reported to be expressed during the late G1 phase (Figure 1a) .
Myc binding to regulatory regions was assessed for 36 genes that are proven or candidate Myc direct targets by performing chromatin immunoprecipitation (ChIP). Myc-DNA complexes were immunoprecipitated at the time points reported above, and semiquantitative PCR performed. All of the genes chosen for this study have been selected on the basis of previous characterization of their responsiveness to Myc. Most of these genes had already been subjected to extensive analysis of their regulatory sequences and Myc responsive regions assessment results from the integration of gene expression, transactivation, EMSA, and ChIP data (www.myc-cancer-gene.org). These studies had been performed in rat, mouse, and human cell types. For six genes, the Myc responsive regions, which had not been previously assessed in rodent cells, were extrapolated by comparative analysis with the human homolog, using the rVISTA algorithm. Based on the reported data, we designed primers to amplify regions that comprise the Myc-responsive E-box elements of Myc upregulated genes, and regions covering the TATA-box or the Inr sequences of the downregulated Cell division cycle 25A Up (Table 1) , some of which had not been previously confirmed by ChIP. When PCR was performed using couples of primers designed outside the Myc-responsive regions, no enrichment was detected (data not shown). Figure 1b reports the ChIP profile of six out of 22 Myc upregulated genes and five out of 14 Myc downregulated genes. Myc binds to the targets throughout the G1 phase in both wt and PMLÀ/ À MEFs, and we could not find any substantial difference in Myc binding levels between the two cell types.
Parallel to the ChIP analysis, the expression profile of the genes analysed by ChIP and of other proven Myc targets (Table 1) was assessed using real-time PCR, and the observed differences were validated by performing the paired Student's t-test (Supplementary Information). In the G1 phase (t6 and t12), which coincides with the peak of Myc protein activity, many of the target genes are more expressed in PMLÀ/À MEFs compared to wt. Figure 1c summarizes the expression data; in G0, most genes do not show differences in the expression levels between the two cell types; however, during the G1 phase (t6 þ t12), many genes, both activated and repressed by Myc, are more expressed in PMLÀ/À cells. Together, 52% of the genes analysed (21 out of 40, see Table 1 ) display an increased expression in PMLÀ/À cells. This number decreases as cells enter the S phase (t16). The expression levels of the upregulated genes return to be comparable between the two cell types as soon as cells exit the G1 phase, while the augmented expression in PMLÀ/À cells shown by downregulated genes during G1 is mostly retained toward the S phase, suggesting a difference of sensitivity between the mechanisms that regulate transcription in the two gene subpopulations.
Myc colocalizes and physically interacts with PML
The observation that PML influences the expression of Myc target genes prompted us to test whether the two proteins could colocalize. Myc and PML are two nuclear proteins; PML localizes to the NB, whereas Myc shows a diffuse speckled subnuclear pattern (Yin et al., 2001) . We cotransfected Myc and PML in HeLa cells, and checked that the localization patterns were comparable to the endogenous ones (Figure 2A, a, b) . Combined immunofluorescence revealed that Myc and PML signals partially overlap in several NB (Figure 2A , a-c). The same results were obtained using Cos-7 and U2OS cells (data not shown). In order to investigate this colocalization further, we performed confocal microscopy analysis on the two endogenous proteins in HeLa (Figure 2A, d-i ) and U2OS cells (not shown), which confirmed that a small, although consistent fraction of Myc protein localizes to the NB, and that Myc accumulates in definite areas (Figure 2A , f', i' and i'').
Parallel to the colocalization observed by immunofluorescence analysis, we investigated the association between Myc and PML by immunoprecipitation. Cos-7 ( Figure 2B , C) and HeLa cells (not shown) were cotransfected with Flag-tagged Myc and HA-tagged PML IV. When lysates were immunoprecipitated with anti-Flag or anti-Myc antibody, a small portion of PML was recovered ( Figure 2B, lanes 2 and 3) . Likewise, Myc was coimmunoprecipitated using anti-PML or anti-HA antibody ( Figure 2C, lanes 1 and 4) . Moreover, PML was also recovered after immunoprecipitation of endogenous Myc in PML transfected NIH-3T3 fibroblasts ( Figure 2D, lane 5) .
To characterize the interaction further, we performed a GST pull-down assay. Three different GST-fused Myc fragments ( Figure 3a) were purified from Escherchia coli (Figure 3b ), and incubated with cellular extracts from PML-transfected HeLa cells. Immunoblot analysis with anti-PML antibody showed that PML specifically interacts with the N-terminal portion of Myc, but not with the other protein fragments (Figure 3c ) or with the GST moiety alone (not shown). The protein fragment interacting with PML includes Myc Box I and II. When Myc Box I is deleted (aa 104-439), no interaction with PML is observed, suggesting that this domain is required for the interaction.
Myc-PML association increases upon proteasome inhibition
Besides its diffuse nucleoplasmic staining, Myc can also distribute around the nucleoli. When overexpressed, the rate of Myc localization to the nucleoli increases, and the same effect is observed if cells are treated with proteasome inhibitors (Arabi et al., 2003) . Recent evidences have demonstrated the recruitment of PML to the perinucleolar zone following proteasome inhibition (Mattsson et al., 2001) . We observed that the nucleolar distribution of overexpressed Myc induced PML sequestration at the nucleoli in several cells ( Figure 4A, a-c) . Therefore, we hypothesized that Myc-PML interaction might be sensitive to the turnover determined by the proteasome-mediated degradation. To test this, HeLa, Cos-7, and U2OS cells were transfected with Myc, and incubated for 5 h with 50 mM MG-132 in DMSO or with DMSO alone. Overexpressed Myc showed the classical nucleoplasmic diffuse and nucleolar pattern, both in untreated or DMSO-treated cells. However, cells treated with the proteasome inhibitor showed an increased distribution of Myc around the nucleoli and in well-defined nuclear speckles ( Figure 4A, d-f ). As the proteasome colocalizes with Myc at the nucleoli after proteasome inhibition, we checked whether this localization is also extended to Myc-containing nuclear speckles. We observed a strong relocalization of the proteasome in Myc nuclear inclusions, which was undetectable in untransfected cells ( Figure 4A, g-i) . To further confirm the specificity of the effect observed, cells were cotransfected with Myc and CBP, or with PML and CBP. After proteasome inhibition, Myc relocalized in the nuclear speckles, whereas CBP does not ( Figure 4A , j-l); furthermore, this effect was never observed in PML and CBP cotransfected cells ( Figure 4A , n and o). Upon Myc transfection, endogenous PML showed a remarkable redistribution into Myc-enriched structures. PML strongly colocalized with Myc in the perinucleolar region ( Figure 4A , p-r), and almost completely in Myc-containing speckles ( Figure 4A , s-u), whereas PML localization was not affected by proteasome inhibition in untransfected cells ( Figure 4A, p-u) . Then, we checked if Myc relocalization with PML after cell treatment with the proteasome inhibitor corresponded to increased interaction. HeLa cells cotransfected with Myc and PML, and treated with MG-132 showed a clear enrichment of Myc-PML coimmunoprecipitation, using either anti-Myc or anti-PML antibodies ( Figure 4B ), thus confirming that proteasome inhibition stabilizes the Myc-PML complex. Myc induces gene expression by direct binding to target DNA and represses transcription by interfering with the transcriptional machinery of the target genes (Levens, 2003) . In this report, we show that the expression level of 50% activated and 57% repressed Myc target genes is significantly increased in PMLÀ/À cells during the G1 phase, when Myc reaches its peak of activity. This effect of PML does not seem to be due to interference with Myc DNA binding, as ChIP performed on wt and PML À/À MEFs shows a comparable enrichment of Myc binding to the regulatory regions of the target genes throughout the G1 phase. Our results indicate that Myc binding to DNA is independent on the presence of PML. As Myc-mediated activation and repression occurs via independent mechanisms, the observation that the two gene categories display the same altered expression profile after PML withdrawal proposes an epistatic role of PML on Myc activity. A total of 24% Myc upregulated genes are more expressed in PMLÀ/À MEFs in G0. Myc shares several upregulated genes with Mad, which requires PML to repress transcription (Khan et al., 2001; Luscher, 2001; Nikiforov et al., 2003) . mad1 is expressed in G0, and is strongly downregulated as cells enter G1 in MEFs (data not shown), whereas myc shows the opposite trend, accounting for the distinct roles of Myc and Mad on target gene expression in the two cell phases. It is possible that reduced Mad-mediated repression in the absence of PML contributes to the expression pattern observed in G0. Of the genes analysed, p21 is the only one that is constitutively more expressed in wt cells. As p21 is also a direct target of p53, p21 misexpression may be determined by p53 defective activity in PMLÀ/À MEFs (Fogal et al., 2000) .
Myc recruitment in the NB and physical interaction with PML opens questions concerning the mechanism by which PML influences Myc transcriptional activity. A small amount of Myc localizes at the NB suggesting transient and dynamic interaction. This is consistent with the data reported for other transcription factors that interact with PML, as well as for other PML interactors, such as CBP (Borden, 2002) . Myc and PML belong to a subset of proteins that translocate to the nucleoli when overexpressed or by inhibition of proteasome-mediated degradation (Arabi et al., 2003) (Mattsson et al., 2001) . In HeLa cells, PML takes several hours to localize in the nucleolus following proteasome inhibition; however, when we overexpress Myc, strong colocalization of the two proteins with the proteasome at the nucleolus and in Myc nuclear inclusions is already detected after 3 h. As Myc localization to the nucleoli is a dynamic and reversible process that engages the proteasome, we hypothesize that Myc accumulation induced by overexpression and proteasome inhibition also stabilizes the dynamic interaction with PML. These data suggest that the interaction between Myc and PML may depend on Myc post-translational status. Myc protein is subjected to several post-translational modifications, phosphorylation, glycosylation, ubiquitination, and acetylation (Salghetti et al., 1999; Sears et al., 2000; Kamemura et al., 2002; Vervoorts et al., 2003) . The balance among these modifications control Myc activity and degradation (Salghetti et al., 1999; Kim et al., 2003; von der Lehr et al., 2003) . As the NB are sites of active post-translational modifications (Pearson et al., 2000; Best et al., 2002; Moller et al., 2003) , our data suggest that PML is involved in the surveillance of Myc activity participating in Myc post-translational modifications. We hypothesize that the lack of PML may alter the balance among the different Myc posttranslational modifications, in a way that renders Myc more efficient as a transcriptional activator than as a repressor.
Materials and methods
Cell culture and synchronization
MEFs (Wang et al., 1998) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% fetal bovine serum (FBS, Invitrogen), 50 mM b-mercaptoethanol, and 100 U/ml penicillin/streptomycin. Cos-7, HeLa, U2OS, and NIH-3T3 cell lines were grown in DMEM, supplemented with 10% FBS (Sigma), and 100 U/ml penicillin/streptomycin.
Transient transfections
Murine c-Myc cDNA in pCMV-2-Flag vector (Sigma) and human PML isoform IV (Bischof et al., 2002) cDNA in pCDNA3-HA (Invitrogen) were used to transfect different cell 
ChIP
Passage 9 MEFs, 80% confluent, were synchronized by starving in DMEM 0.1% FBS, for 72 h; then 20% FBS DMEM was readded and ChIP was performed at 0, 6, 12, 16, and 20 h post reinduction. Cells were fixed for 20 min with crosslinking solution (11% formaldehyde, 0.1 M NaCl, 1 mM Na-EDTA pH 8, 0.5 mM Na-EGTA pH 8, 50 mM HEPES pH 8, 1/10 volume (Vol) added to the medium), and blocked in 0.125 M glycine in PBS at room temperature (RT). Cells were collected in 10 ml buffer A (0.25% Triton X-100, 10 mM Na-EDTA pH 8, 0.5 mM Na-EGTA pH 8, 10 mM Tris-HCl pH 8, anti-proteases (10 mg/ml aprotinin, 10 mg/ml leupeptin, 5 mg/ml pepstatin), anti-phosphatases (1 mM sodium orthovanadate, 10 mM tetra-sodium pyrophosphate, 10 mM NaF), and 0.5 mM PMSF), incubated 10 min at 41C on a wheel, centrifuged for 5 min at 1500 r.p.m., and resuspended in 10 ml of buffer B (0.2 M NaCl, 10 mM Na-EDTA pH 8, 0.5 mM Na-EGTA pH 8, 10 mM Tris-HCl pH 8, 0.5 mM PMSF, anti-proteases, and antiphosphatases). Incubation and centrifugation steps were repeated, and the pellets were resuspended in 440 ml of sonication buffer (0.2 M NaCl, 10 mM Na-EDTA pH 8, 0.5 mM Na-EGTA pH 8, 10 mM Tris-Cl pH 8, anti-proteases, anti-phosphatases, and 0.5 mM PMSF). Samples were sonicated for 3 Â 30 s, yielding genomic DNA fragments with a bulk size of 300-2000 base pairs, and the sonication buffer was adjusted to an RIPA buffer by adding 1% Triton X-100, 0.1% sodium dodecyl sulphate (SDS), and 0.1% sodium deoxycholate (DOC) final concentration. Samples were incubated for 10 min on a wheel at 41C and then centrifuged for 10 min at 10 000 r.p.m. In all, 50 ml/sample were kept to recover total DNA input, and ChIP was performed, either with 2 mg of antiMyc N-262 or without antibody, as described in Boyd and Farnham (1997) . After crosslinking reversal, protein extraction, and ethanol precipitation, DNA was resuspended in TE, 50 ml for total input, and 100 ml for ChIP samples. ChIP DNA (1-2 ml) was used for PCR analysis. PCR was performed using HotStarTaq (Qiagen) and the primers listed in Supplementary Information.
RNA extraction and real-time PCR analysis
MEFs total RNA was extracted with RNeasy mini Kit (Qiagen) and quantified. cDNA was prepared using Omniscript reverse transcriptase (Qiagen), according to the manufacturer's instructions. Real-time quantitative PCR was performed on an Applied Biosystems 7000 machine using the 2 Â Sybr Green Master Mix (Applied Biosystems), using the primer pairs listed in Supplementary Information. Gene expression values are the results of at least four experiments. Gapd was used as reference gene.
Coimmunoprecipitation
After transfection, cells were harvested in 0.5 mM PMSF in PBS and centrifuged for 1 min at 1000 r.p.m. at 41C. Pellets were resuspended in 500 ml PTG buffer (10 mM Tris-Cl pH 8, 2 mM DTT, 10% glycerol, 1 mM MgCl 2 , 1 mM PMSF, cocktail inhibitor SIGMA, and anti-phosphatases) and incubated for 10 min on ice; 0.5% NP-40 final concentration was added, samples were incubated for 3-4 min on a wheel at 41C, and centrifuged for 5 min at 800 r.p.m. at 41C. Nuclei were resuspended in Ip buffer (0.25% NP-40, 2 mM DTT, cocktail inhibitor (Sigma), 1 mM PMSF, and anti-phosphatases in PBS), and immuprecipitation performed as described (Reymond et al., 2001) . Proteins were transferred on PVDF membranes (Pharmacia), subjected to Western blot analysis and revealed by chemiluminescence using Super Signal Pico (Pierce).
GST pull-down
Myc fragments (aa 1-178, 173-349, and 104-349) were fused to the glutathione S-transferase in a pGEX-4T-1 (Amersham Biosciences) and produced in E. coli. PML-transfected HeLa cells were collected and resuspended in 600 ml lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 200 mM NaCl, 0.5 mM DTT, 1% Triton X-100, 1 mM PMSF, 30 ml cocktail inhibitor, Sigma), sonicated 3 Â 5 s and kept on a wheel for 30 min at 41C. The sample was centrifuged at 14 000 r.p.m. for 30 min, and the supernatant was added to the agarose beads bound to GST alone or to the specific GST-fusion proteins, and incubated overnight at 41C. Samples were centrifuged at 1500 g for 4 min, and beads were washed four times in the lysis buffer, and subjected to SDS/PAGE.
Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde in PBS for 5 min at RT, permeabilized in 0.2%. Triton X-100 in PBS for 30 min at RT, and blocked for 1 h in 0.1% Triton X-100, 10% goat serum, in PBS. Cells were incubated for 3 h at RT with primary antibodies, followed by 1 h incubation at RT, with FITCconjugated anti-mouse and/or TRITC-conjugated anti-rabbit antibodies (Dako Glostrup), or with Cy2-conjugated antirabbit antibodies and/or Cy3-conjugated anti-mouse antibodies (Jackson ImmunoResearch)
To detect endogenous Myc, after incubation with the primary antibody, cells were incubated with Biotin-conjugated goat anti-rabbit antibodies for 1 h, followed by 1 h with Cy3-conjugated streptavidin (Sigma). Cells were then mounted with Vecta Shield (Vector), and observed under a Zeiss-Axioplan 2 microscope or Leica TCS SP2 AOBS laser scanning confocal microscope.
